苯并噻吩-2-氨基甲酸叔丁酯 | 89673-36-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 苯并噻吩-2-氨基甲酸叔丁酯
• 英文名称: 2-(tert-butoxycarbonylamino)benzothiophene
• 英文别名: 2-t-butoxycarbonylaminobenzothiophene；benzo[b]thiophen-2-yl-carbamic acid tert-butyl ester；1,1-dimethylethyl 1-benzothien-2-ylcarbamate；tert-Butyl benzo[b]thiophen-2-ylcarbamate；tert-butyl N-(1-benzothiophen-2-yl)carbamate
• CAS: 89673-36-9
• 化学式: C₁₃H₁₅NO₂S
• mdl: MFCD22056377
• 分子量: 249.334
• InChiKey: CNFLHJOYSZBEEL-UHFFFAOYSA-N

物化性质

• 熔点：
  100-101 °C(Solv: ethanol (64-17-5))
• 沸点：
  333.4±15.0 °C(Predicted)
• 密度：
  1.234

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  66.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: tert-Butyl N-(1-benzothiophen-2-yl)carbamate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl N-(1-benzothiophen-2-yl)carbamate
CAS number: 89673-36-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H15NO2S
Molecular weight: 249.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  苯并噻吩-2-氨基甲酸叔丁酯 在 三氟乙酸 、 sodium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以91%的产率得到苯并[B]噻吩-2-胺
  参考文献：
  名称：

  [EN] REVERSED PYRIMIDINONE COMPOUNDS AS CALCILYTICS
  [FR] COMPOSES A BASE DE PYRIMIDINONE INVERSEE SERVANT DE CALCILYTIQUES

  摘要：

  本发明公开了钙离子受体拮抗化合物及其制备方法，同时还提供了使用该钙离子受体拮抗化合物的方法。

  公开号：

  WO2006041968A1
• 作为产物：
  描述：

  苯并噻吩-2-羰酰氯 在 sodium azide 作用下， 以 水 、 丙酮 为溶剂， 反应 2.25h， 生成 苯并噻吩-2-氨基甲酸叔丁酯
  参考文献：
  名称：

  A Convenient Preparation of Haloaminobenzo[b]thiophene Derivatives

  摘要：

  DOI：

  10.1055/s-1983-30577

文献信息

• Imidazopyrazines as protein kinase inhibitors
  申请人：Zhao Lianyun

  公开号：US20070117804A1

  公开（公告）日：2007-05-24

  In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.

  本发明的多种实施例提供了一类新型的咪唑吡嗪化合物，作为蛋白质和/或检查点激酶的抑制剂，包括制备这类化合物的方法、包含一个或多个这类化合物的药物组合物、制备包含一个或多个这类化合物的药物制剂的方法，以及使用这类化合物或药物组合物治疗、预防、抑制或改善与蛋白质或检查点激酶相关的一个或多个疾病的方法。
• [EN] SULFONAMIDES AS TRPM8 MODULATORS<br/>[FR] SULFONAMIDES COMME MODULATEURS TRPM8
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009012430A1

  公开（公告）日：2009-01-22

  ABSTRACT Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein A, B, G, Y, R1, R2, R3, and R4 are defined herein.

  摘要：本文披露了用于治疗各种疾病、综合症、症状和疾病的化合物、组合物和方法，包括疼痛。这些化合物由以下公式（I）表示：其中A、B、G、Y、R1、R2、R3和R4在此处定义。
• SULFONAMIDES AS TRPM8 MODULATORS
  申请人：Macielag Mark J.

  公开号：US20100160289A1

  公开（公告）日：2010-06-24

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) and Formula (II) as follows: wherein Y, R 1 , R 2 , R 3 , R 4 , R A , and R B are defined herein.

  揭示了用于治疗各种疾病、综合症、症状和疾病的化合物、组合物和方法，包括疼痛。这些化合物由以下的化学式(I)和化学式(II)所代表：其中Y、R1、R2、R3、R4、RA和RB在此定义。
• Methods for inhibiting protein kinases
  申请人：Guzi J. Timothy

  公开号：US20070105864A1

  公开（公告）日：2007-05-10

  The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim-1 kinase, and tyrosine kinase using imidazo[1,2-a]pyrazine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.

  本发明提供了利用咪唑并[1,2-a]吡嗪化合物抑制来自AKT、检查点激酶、枢纽激酶、Pim-1激酶和酪氨酸激酶的蛋白激酶的方法，以及利用这些化合物治疗、预防、抑制或改善与蛋白激酶相关的一种或多种疾病的方法。
• Reversed Pyrimidinone Compounds as Calcilytics
  申请人：Marquis Jr W. Robert

  公开号：US20070270446A1

  公开（公告）日：2007-11-22

  Calcilytic compounds and methods of preparing them are disclosed. Methods of using the calcilytic compounds are also provided.

  本发明公开了Calcilytic化合物及其制备方法。还提供了使用Calcilytic化合物的方法。